Literature DB >> 25796344

Vascular smooth muscle cells contribute to APOL1-induced podocyte injury in HIV milieu.

Xiqian Lan1, Hongxiu Wen1, Moin A Saleem2, Joanna Mikulak3, Ashwani Malhotra1, Karl Skorecki4, Pravin C Singhal5.   

Abstract

Clinical reports have demonstrated that higher rates of non-diabetic glomerulosclerosis in African Americans can be attributed to two coding sequence variants (G1 and G2) in the APOL1 gene; however, the underlying mechanism is still unknown. Kidney biopsy data suggest enhanced expression of APOL1/APOL1 variants (Vs) in smooth muscle cells (SMCs) of renal vasculature. Since APOL1 is a secretory protein of relatively low molecular weight (41kDa), SMCs may be a contributory endocrine/paracrine source of APOL1 wild type (WT)/APOL1Vs in the glomerular capillary perfusate percolating podocytes. In the present study, we tested the hypothesis that an HIV milieu stimulated secretion of APOL1 and its risk variants by arterial SMCs contributes to podocyte injury. Human umbilical artery smooth muscle cells (HSMCs)-treated with conditioned media (CM) of HIV-infected peripheral mononuclear cells (PBMC/HIV-CM), CM of HIV-infected U939 cells, or recombinant IFN-γ displayed enhanced expression of APOL1. Podocytes co-cultured in trans-wells with HSMCs-over expressing APOL1WT showed induction of injury; however, podocytes co-cultured with HSMC-over expressing either APOL1G1 or APOL1G2 showed several folds greater injury when compared to HSMC-over expressing APOL1WT. Conditioned media collected from HSMC-over-expressing APOL1G1/APOL1G2 (HSMC/APOL1G1-CM or HSMC/APOL1G2-CM) also displayed higher percentages of injured podocytes in the form of swollen cells, leaky lysosomes, loss of viability, and enhanced sensitivity to adverse host factors when compared to HSMC/APOL1WT-CM. Notably, HSMC/APOL1WT-CM promoted podocyte injury only at a significantly higher concentrations compared to HSMC/APOL1G1/G2-CM. We conclude that HSMCs could serve as an endocrine/paracrine source of APOL1Vs, which mediate accelerated podocyte injury in HIV milieu.
Copyright © 2015 Elsevier Inc. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2015        PMID: 25796344      PMCID: PMC4433601          DOI: 10.1016/j.yexmp.2015.03.020

Source DB:  PubMed          Journal:  Exp Mol Pathol        ISSN: 0014-4800            Impact factor:   3.362


  43 in total

Review 1.  Secretory functions of smooth muscle: cytokines and growth factors.

Authors:  William T Gerthoffer; Cherie A Singer
Journal:  Mol Interv       Date:  2002-11

2.  Population-based risk assessment of APOL1 on renal disease.

Authors:  David J Friedman; Julia Kozlitina; Giulio Genovese; Prachi Jog; Martin R Pollak
Journal:  J Am Soc Nephrol       Date:  2011-10-13       Impact factor: 10.121

3.  Vps34 deficiency reveals the importance of endocytosis for podocyte homeostasis.

Authors:  Wibke Bechtel; Martin Helmstädter; Jan Balica; Björn Hartleben; Betina Kiefer; Fatima Hrnjic; Christoph Schell; Oliver Kretz; Shuya Liu; Felix Geist; Dontscho Kerjaschki; Gerd Walz; Tobias B Huber
Journal:  J Am Soc Nephrol       Date:  2013-03-14       Impact factor: 10.121

4.  APOL1 variants and kidney disease in people of recent African ancestry.

Authors:  Giulio Genovese; David J Friedman; Martin R Pollak
Journal:  Nat Rev Nephrol       Date:  2013-02-26       Impact factor: 28.314

5.  Hypertension-misattributed kidney disease in African Americans.

Authors:  Karl L Skorecki; Walter G Wasser
Journal:  Kidney Int       Date:  2013-01       Impact factor: 10.612

6.  Lipid profile changes by high activity anti-retroviral therapy.

Authors:  M Duro; R Sarmento-Castro; C Almeida; R Medeiros; I Rebelo
Journal:  Clin Biochem       Date:  2013-01-04       Impact factor: 3.281

7.  A novel immunogen to modulate cytokine production and promote immune system reconstitution in HIV-AIDS.

Authors:  Jack L Segal; John F Thompson; Richard A Charter
Journal:  Am J Ther       Date:  2012-09       Impact factor: 2.688

8.  The absence of intrarenal ACE protects against hypertension.

Authors:  Romer A Gonzalez-Villalobos; Tea Janjoulia; Nicholas K Fletcher; Jorge F Giani; Mien T X Nguyen; Anne D Riquier-Brison; Dale M Seth; Sebastien Fuchs; Dominique Eladari; Nicolas Picard; Sebastian Bachmann; Eric Delpire; Janos Peti-Peterdi; L Gabriel Navar; Kenneth E Bernstein; Alicia A McDonough
Journal:  J Clin Invest       Date:  2013-04-24       Impact factor: 14.808

9.  A cytosolic source of calcium unveiled by hydrogen peroxide with relevance for epithelial cell death.

Authors:  J Castro; C X Bittner; A Humeres; V P Montecinos; J C Vera; L F Barros
Journal:  Cell Death Differ       Date:  2004-04       Impact factor: 15.828

10.  APOL1 null alleles from a rural village in India do not correlate with glomerulosclerosis.

Authors:  Duncan B Johnstone; Vijay Shegokar; Deepak Nihalani; Yogendra Singh Rathore; Leena Mallik; Vasant Zare; H Omer Ikizler; Rajaram Powar; Lawrence B Holzman
Journal:  PLoS One       Date:  2012-12-26       Impact factor: 3.240

View more
  17 in total

1.  Apolipoprotein L1 (APOL1) risk variant toxicity depends on the haplotype background.

Authors:  Herbert Lannon; Shrijal S Shah; Leny Dias; Daniel Blackler; Seth L Alper; Martin R Pollak; David J Friedman
Journal:  Kidney Int       Date:  2019-08-01       Impact factor: 10.612

2.  APOL1 Kidney Risk Variants Induce Cell Death via Mitochondrial Translocation and Opening of the Mitochondrial Permeability Transition Pore.

Authors:  Shrijal S Shah; Herbert Lannon; Leny Dias; Jia-Yue Zhang; Seth L Alper; Martin R Pollak; David J Friedman
Journal:  J Am Soc Nephrol       Date:  2019-09-26       Impact factor: 10.121

Review 3.  Ten years in: APOL1 reaches beyond the kidney.

Authors:  Joshua S Waitzman; Jennie Lin
Journal:  Curr Opin Nephrol Hypertens       Date:  2019-07       Impact factor: 2.894

4.  APOL1-Mediated Cell Injury Involves Disruption of Conserved Trafficking Processes.

Authors:  Etty Kruzel-Davila; Revital Shemer; Ayala Ofir; Ira Bavli-Kertselli; Ilona Darlyuk-Saadon; Pazit Oren-Giladi; Walter G Wasser; Daniella Magen; Eid Zaknoun; Maya Schuldiner; Adi Salzberg; Daniel Kornitzer; Zvonimir Marelja; Matias Simons; Karl Skorecki
Journal:  J Am Soc Nephrol       Date:  2016-11-18       Impact factor: 10.121

5.  Most ApoL1 Is Secreted by the Liver.

Authors:  Khuloud Shukha; Jessica L Mueller; Raymond T Chung; Michael P Curry; David J Friedman; Martin R Pollak; Anders H Berg
Journal:  J Am Soc Nephrol       Date:  2016-12-08       Impact factor: 10.121

6.  Protein domains of APOL1 and its risk variants.

Authors:  Xiqian Lan; Hongxiu Wen; Rivka Lederman; Ashwani Malhotra; Joanna Mikulak; Waldemar Popik; Karl Skorecki; Pravin C Singhal
Journal:  Exp Mol Pathol       Date:  2015-06-17       Impact factor: 3.362

Review 7.  APOL1 and kidney cell function.

Authors:  Vinod Kumar; Pravin C Singhal
Journal:  Am J Physiol Renal Physiol       Date:  2019-06-26

Review 8.  APOL1 Nephrotoxicity: What Does Ion Transport Have to Do With It?

Authors:  Opeyemi A Olabisi; John F Heneghan
Journal:  Semin Nephrol       Date:  2017-11       Impact factor: 5.299

Review 9.  Apolipoprotein L1 and Kidney Disease in African Americans.

Authors:  David J Friedman; Martin R Pollak
Journal:  Trends Endocrinol Metab       Date:  2016-03-03       Impact factor: 12.015

10.  APOL1-G0 or APOL1-G2 Transgenic Models Develop Preeclampsia but Not Kidney Disease.

Authors:  Leslie A Bruggeman; Zhenzhen Wu; Liping Luo; Sethu M Madhavan; Martha Konieczkowski; Paul E Drawz; David B Thomas; Laura Barisoni; John R Sedor; John F O'Toole
Journal:  J Am Soc Nephrol       Date:  2016-03-29       Impact factor: 10.121

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.